PETVW — PetVivo Holdings, Inc.

Summary of PETVW Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenues: For the nine months ended December 31, 2025, revenues totaled $887,000, a slight decrease of 2% year-over-year. This included $400,800 from Spryng products and $486,000 from PrecisePRP products.
• Gross Profit: Gross profit was $551,500, representing 62.2% of revenues, down from 89% in the same period last year due to lower margins from PrecisePRP.
• Operating Expenses: Total operating expenses decreased by 2% to $6.7 million, attributed to cost reductions in general and administrative and R&D expenses.
• Net Loss: The net loss was $7.5 million, or $0.27 per share, compared to a loss of $6 million, or $0.30 per share, in the prior year.
• Cash Flow: Net cash used in operating activities was $5.3 million, primarily due to increased inventory purchases for PrecisePRP.
• Balance Sheet: Current assets were $1.4 million, with current liabilities significantly reduced to $980,000, leading to working capital of $395,000.

2. Strategic Updates and Business Highlights

• Product Launches: The company is advancing its flagship product, Spryng, and has launched PrecisePRP, which has received positive feedback from veterinarians.
• New Partnerships: PETVW has formed strategic alliances, including a 10-year licensing agreement with Digital Landia for the AgenticPet AI technology, aimed at reducing veterinary customer acquisition costs.
• PetVivo AI Platform: The new AI-powered SaaS platform for veterinarians is in beta testing, showing a significant reduction in customer acquisition costs and creating a new recurring revenue stream with high gross margins.
• International Expansion: The company is making strides in international markets, including Canada and Mexico, with plans for product launches in these regions.
• Regulatory Milestone: Health Canada has recognized Spryng as a veterinary medical device, opening up new market opportunities in Canada.

3. Forward Guidance and Outlook

• Sales Momentum: The company anticipates continued sales growth and market penetration through fiscal 2026 and beyond, with expectations of capitalizing on the expanding U.S. and international animal health markets.
• Sales Strategy: PETVW is in discussions to partner with an outside sales and marketing firm to enhance its distribution network and sales efforts.
• Product Pipeline: The company is focused on advancing its pipeline of new products, including functional biomaterials, with potential commercialization by late 2026 or early 2027.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The slight decrease in revenues was primarily due to lower sales of Spryng, attributed to the absence of promotional activities that had previously boosted sales.
• Increased Operating Loss: The operating loss increased by 2%, driven by higher sales and marketing expenses related to the new product rollout.
• Market Conditions: The life sciences microcap market is experiencing a correction, impacting stock performance and potential uplisting plans to NASDAQ or New York Amex.
• Customer Adoption: The transition to new products and technologies may require time and education for veterinarians, which could delay revenue recognition.

5. Notable Q&A Insights

• Guidance Clarification: Management was cautious about previous revenue guidance and emphasized that recent sales declines were due to strategic changes in promotional activities.
• CapEx for Digital Landia: The rollout of the PetVivo AI system is expected to have minimal capital expenditure, with operational costs primarily related to marketing and promotion.
• Revenue Model: The new AI platform operates on a freemium to premium model, with expectations of converting a significant percentage of beta users to paying customers.
• Support for Ecosystem: Digital Landia is responsible for ongoing support and updates for the AI platform, which is designed to enhance veterinary practices and customer engagement.

Overall, PETVW is navigating a transformative phase with new product launches and strategic partnerships, although it faces challenges with revenue fluctuations and market conditions. The outlook remains cautiously optimistic as the company positions itself for future growth.